Other therapies for BPH patients: desmopressin, anti-cholinergic, anti-inflammatory drugs, and botulinum toxin.
The usual treatments of benign prostate hyperplasia (BPH) including the alpha-blockers, the inhibitors of the 5-alpha reductase and the phytotherapy drugs allow significant improvements of the lower urinary tracts symptoms (LUTS). However, some patients are not responders or have side effects due to the treatments. Other therapeutic approaches described in the literature are possible in order to alleviate the LUTS. The anti-cholinergic drugs seem to be efficient against the irritating symptoms even if they are supposed to be contra-indicated when there is BPH. Anti-diuretic hormone could be useful to treat nocturia due to diuresis reversal. Inflammation is a part of the underlying mechanisms of BPH and as such the role of the anti-inflammatory drugs has to be revised. Eventually, botulinum toxin is more and more used for patients with neurological bladder and could also have a role in LUTS. If the coming clinical studies on those different treatments confirm the preliminary results, the learning societies in charge of the guidelines would have to update the decision trees by adding these new therapeutic approaches.
Azzouzi
Abdel-Rahmène
AR
Department of Urology, CHU, Angers, France.
Fourmarier
Marc
M
Desgrandchamps
Francois
F
Ballereau
Charles
C
Saussine
Christian
C
Haillot
Olivier
O
Lukacs
Bertrand
B
Devonec
Marian
M
de la Taille
Alexandre
A
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D050034:Antidiuretic Agents / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D050034:Antidiuretic Agents; D018680:Cholinergic Antagonists; D001905:Botulinum Toxins; D003894:Deamino Arginine Vasopressin